The Use of Next-Generation Sequencing in Treating Non-Squamous Non-Small-Cell Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Goeffrey Oxnard and Lauren Ritterhouse consider how next-generation sequencing (NGS) informs treatment of lung cancer patients in providing information on tumor mutational burden, microsatellite instability, unique targetable genomic signatures, as well as novel targets that may be best addressed in a clinical trial.

Related Videos

October 23, 2018

The Role of Tumor Mutational Burden in Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

December 18, 2018

Reimbursement Challenges and Solutions with Molecular Biomarker Testing

Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.